Lung Cancer Clinical Trial
Supportive Care Mobile Application for Patients With NSCLC
Summary
This research study is looking at the role of a supportive care mobile app in improving symptoms, coping skills, and quality of life in patients with non-small cell lung cancer.
Full Description
This research study is a Feasibility Study, which is the first-time investigators are examining this supportive care mobile app intervention. The goal of this research study is to refine and examine the feasibility and benefits of a supportive care mobile app to improve symptoms, coping skills, and quality of life in patients with non-small cell lung cancer. Many people diagnosed with lung cancer experience challenging symptoms and increased stress. To help address these concerns, this study is exploring how a mobile application (app) intervention, designed specifically for people with lung cancer, can expand the availability of much needed supportive care services.
The research study procedures include:
A supportive care mobile app consisting of six intervention modules that focus on components of wellbeing, such as physical, social, functional, and emotional wellbeing
Questionnaires asking about demographic information (e.g., gender, ethnicity, income) and participants' experience with cancer (e.g., quality of life, symptoms)
Data collection from participants medical records
After completing a baseline study questionnaire, participants will be randomized into two (2) study groups:
Usual Care Group: Participants will receive standard oncology care and attend their regular clinic visits. Study staff will monitor participant use of supportive care services.
Intervention Group: Participants will be provided with a study-issued tablet computer to access the mobile app and receive tutorial and instructions for how to use the app.
Participants will be in this research study for 12-14 weeks.
It is expected that about 120 people will take part in this research study.
The sponsors of this study are the National Comprehensive Cancer Network (NCCN) and AstraZeneca Pharmaceuticals. NCCN is a non-profit alliance of leading cancer centers across the United States, and AstraZeneca Pharmaceuticals is a global bio-pharmaceutical company. These two sponsors are together providing funding and oversight for the conduct of this research study.
Eligibility Criteria
Inclusion Criteria:
Age >18 years
Diagnosed with unresectable Stage III or IV NSCLC in the past eight weeks and receiving first-line therapy with palliative intent (per clinician documentation in the electronic health record)
Eastern Cooperative Oncology Group Performance Status = 0-3
Plan to receive oncology care at one of the participating study sites
Ability to read and respond to questions in English
Exclusion Criteria:
Significant uncontrolled psychiatric disorder (e.g., psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (e.g., dementia, cognitive impairment), which the treating oncology clinician reports would prohibit the ability to participate in study procedures
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Boston Massachusetts, 02114, United States More Info
Principal Investigator
Danvers Massachusetts, 01923, United States More Info
Principal Investigator
Newton Massachusetts, 02462, United States More Info
Principal Investigator
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.